SCHEMBL4488940

SCHEMBL4488940

Cc1cc(Cl)ccc1-c1cnc(C#C[Si](C)(C)C)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.38
GRM5 P41594 1/20 0.34
IDO1 P14902 1/20 0.33
MAPT P10636 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
CASP3 P42574 1/20 0.32
HSP90AB1 P08238 1/20 0.31
ACACB O00763 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
ALOX12 P18054 1/20 0.31
MAPK10 P53779 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
KDM5B Q9UGL1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477300 0.87 MAPT (0.40) GRM5MAPTNPC1RAB9AHSP90AB1
SCHEMBL4475272 0.81 NOTUM (0.38) NOTUMGRM5IDO1MAPTCASP3
SCHEMBL11998364 0.78 ACACB (0.46) NOTUMNPC1RAB9AACACBMEN1
SCHEMBL4469264 0.73 NOTUM (0.41) NOTUMGRM5IDO1MAPTCASP3
SCHEMBL4477259 0.73 ALOX5AP (0.49) NOTUM
SCHEMBL8973225 0.70 ADRA2A (0.36) GRM5MCHR1
SCHEMBL17404393 0.69 FFAR1 (0.42) NOTUMGRM5MAPTNPC1RAB9A
SCHEMBL5406690 0.68 NOTUM (0.41) NOTUMGRM5IDO1NPC1RAB9A
SCHEMBL26262200 0.67 ALOX5AP (0.41) NOTUMCYP1A2CYP3A4CYP2C19ALDH1A1
SCHEMBL4474343 0.66 HSP90AA1 (0.41) IDO1MAPTNPC1RAB9AHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 NOTUM 2244/4885GRM5 119/4885IDO1 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.